FDA confirms new infections linked to Tysabri
Submitted by admin on September 22, 2009 – 2:00 pmNo Comment | 43 views
The San Francisco Chronicle reports that the FDA has confirmed three new cases of a potentially lethal brain inflammation linked to the multiple sclerosis drug Tysabri. The article notes that there have been 13 reported cases of progressive multifocal leukoencephalopathy, or PML, since mid-2006. While the disease is rare, the FDA says the risk appears to increase as patients remain on Tysabri.
Tysabri was approved in November 2004 and pulled from the market the next year due to reports of PML. It was reintroduced in July 2006, and Biogen said it is used by 43,000 patients.
Related posts:
